natgillin/translations-raw huggingface dataset:
Women with a history of tubal disease are at risk of ectopic pregnancy, whether the pregnancy is obtained by spontaneous conception or with fertility treatments.
Pri ženskah z boleznijo jacevodov v anamnezi, obstaja tveganje zunajmaternične nosečnosti, ne glede na to ali pride do zanositve spontano ali z zdravljenjem neplodnosti.
Nevertheless there is a possibility that OHSS may occur, which is further described in section 4.4.
Vendar pa lahko pričakujemo pojav sindroma hiperstimulacije jajčnikov, ki je podrobno opisan v poglavju 4.4.
Therefore, administration of less than one vial of Pergoveris daily may provide too little LH-activity to ensure adequate follicular development.
Zato lahko dajanje manj kot ene viale zdravila Pergoveris dnevno, rezultira v premajhni aktivnosti LH za zagotovitev ustreznega razvoja foliklov.
They will supervise your first injection.
Pri prvem injiciranju vas bodo nadzirali.
• Pergoveris is supplied in packs of 1, 3 and 10 vials of powder with the corresponding number of solvent's vials (1, 3 and 10 vials).
• Zdravilo Pergoveris je na voljo v pakiranjih po 1, 3 in 10 vial s praškom z ustreznim številom vial vehikla (1, 3 in 10 ).
The medicine must be administered immediately after reconstitution.
Zdravilo morate uporabiti takoj po pripravi.
In the stimulation of follicular development in anovulatory women deficient in LH and FSH, the primary effect resulting from administration of lutropin alfa is an increase in oestradiol secretion by the follicles, the growth of which is stimulated by FSH.
Pri stimulaciji razvoja foliklov pri ženskah brez ovulacije s pomankanjem LH in FSH, je primarni učinek dajanja lutropina alfa povečanje izločanja estradiola iz foliklov, katerih rast je spodbujena z FSH.
Pergoveris is not indicated during breast-feeding.
Zdravilo Pergoveris ni indicirano med dojenjem.
Women who have ever had blocked or damaged fallopian tubes (tubal disease) are at risk of pregnancy where the embryo is implanted outside the womb (ectopic pregnancy).
Pri ženskah, ki so imele neprehodne ali poškodovane jajcevode (bolezen jajcevodov), obstaja tveganje nosečnosti, kjer se zarodek vgnezdi zunaj maternice (zunajmaternične nosečnosti).
Pharmacokinetic/pharmacodynamic relationships There is no pharmacokinetic interaction with follitropin alfa when administered simultaneously.
Farmakokinetično/farmakodinamično razmerje Pri sočasnem dajanju s folitropinom alfa ni farmakokinetičnih interakcij.
No teratogenic effect of such gonadotropins has been reported in animal studies.
Študije na živalih ne kažejo teratogenih učinkov takih gonadotropinov.
• A sharps disposal bin (not included in the pack)
•vsebnik za odlaganje ostrih odpadkov (ni vključen v pakiranju).
For instructions on the use of this medicinal product, see section 6.6.
Za navodila glede uporabe zdravila glejte poglavje 6.6.
Your doctor or nurse will have already advised you where to inject (e.g. tummy, front of thigh).
Zdravnik ali medicinska sestra sta vas že poučila o mestu injiciranja injekcije (npr. v trebuh, sprednjo stran stegna).
There may be a degree of interpatient variability in response to FSH/LH administration, with a poor response to FSH/LH in some patients.
Razpon odziva na zdravljenje s FSH/LH se lahko med bolnicami razlikuje, pri nekaterih bolnicah je odziv na dajanje FSH/LH zelo majhen.
In LH and FSH deficient women (hypogonadotrophic hypogonadism), the objective of Pergoveris therapy is to develop a single mature Graafian follicle from which the oocyte will be liberated after the administration of human chorionic gonadotrophin (hCG).
Pri ženskah s pomanjkanjem LH in FSH (hipogonadotropni hipogonadizem) je cilj zdravljenja z zdravilom Pergoveris razvoj enega samega dozorelega Graafovega folikla, iz katerega se bo po dajanju humanega horionskega gonadotropina (hCG-ja) sprostil oocit.
• Your doctor or nurse will show you how to use the Pergoveris pre-filled pen to inject the medicine.
• Vaš zdravnik ali medicinska sestra vam bo pokazala, kako uporabiti zdravilo Pergoveris napolnjen injekcijski peresnik za injiciranje zdravila.
Therefore, administration of Pergoveris containing less than 75 IU r-hLH daily may provide too little LH-activity to ensure adequate follicular development.
Zato lahko dajanje zdravila Pergoveris, ki vsebuje manj kot 75 i.e. r-hLH dnevno rezultira v premajhni aktivnosti LH za zagotovitev ustreznega razvoja foliklov.
• breast pain
• bolečine v prsih
In clinical trials, patients with severe FSH and LH deficiency were defined by an endogenous serum LH level < 1.2 IU/L as measured in a central laboratory.
V kliničnih preskušanjih so bile bolnice s hudim pomanjkanjem FSH in LH opredeljene na podlagi serumske ravni endogenega LH < 1,2 i.e./l, izmerjene v centralnem laboratoriju.
In clinical trials, these patients were defined by an endogenous serum LH level < 1.2 IU/L.
V kliničnih preskušanjih so te bolnice opredelili glede na serumsko raven endogenega LH < 1,2 i.e./l.
• fibroid tumours of the uterus incompatible with pregnancy
• fibroidnih tumorjih maternice, ki niso združljivi z nosečnostjo.
• When the needle is out of the skin, release the dose setting knob.
• Ko je igla iz kože, spustite gumb za nastavitev odmerka.
• LH stimulates the release of the eggs.
• LH stimulira sproščanje jajčec.
Do not use Pergoveris with other medicines in the same injection, except for follitropin alfa, if prescribed by your doctor.
Zdravila Pergoveris se ne sme uporabljati z drugimi zdravili v isti injekcijski brizgi, razen s folitropinom alfa, če tako predpiše zdravnik.
The most commonly reported adverse reactions are headache, ovarian cysts and local injection site reactions (e.g. pain, erythema, haematoma, swelling and/or irritation at the site of injection).
Neželeni učinki, o katerih so najpogosteje poročali so glavobol, ciste jajčnikov in lokalne reakcije na mestu injiciranja (npr. bolečina, eritem, hematom, oteklina in/ali razdraženost na mestu injiciranja).
• primary ovarian failure
• primarni odpovedi jajčnikov
• Verify you dialed the right dose before injecting (column 6).
• Pred injiciranjem preverite, da ste izbrali pravi odmerek (stolpec 6).
• Record your prescribed dose (column 5).
• Zabeležite predpisani odmerek (stolpec 5).
2 Hold the pen with the needle pointing upward.
2 Peresnik držite z iglo navzgor.
Pergoveris contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially “sodium-free”.
Zdravilo Pergoveris vsebuje manj kot 1 mmol natrija (23 mg) na odmerek, kar v bistvu pomeni „brez natrija“.
These may be the symptoms of ovarian hyperstimulation syndrome (OHSS).
To so lahko simptomi sindroma hiperstimulacije jajčnikov (OHSS).
Do not use Pergoveris with other medicines in the same injection.
Zdravila Pergoveris se ne sme uporabljati z drugimi zdravili v isti injekcijski brizgi.
What Pergoveris looks like and contents of the pack
Izgled zdravila Pergoveris in vsebina pakiranja
If less than the recommended dose daily is used, the follicular response may be unsatisfactory because the amount of lutropin alfa may be insufficient (see section 5.1).
Pri uporabi dnevnega odmerka zdravila Pergoveris, ki je manjši od priporočenega, je lahko razvoj foliklov nezadosten zaradi premajhne količine lutropina alfa (glejte poglavje 5.1).
Follitropin alfa and lutropin alfa have shown the same pharmacokinetic profile as follitropin alfa and lutropin alfa separately.
Folitropin alfa in lutropin alfa kažeta enak farmakokinetični profil, kot folitropin alfa in lutropin alfa vsak posebej.
Pergoveris must be reconstituted with the solvent before use by gentle swirling.
Zdravilo Pergoveris morate pred uporabo rekonstituirati z vehiklom z blagim vrtinčenjem.
Abdominal pain, abdominal distension, abdominal discomfort, nausea, vomiting, diarrhoea Reproductive system and breast disorders Very common:
bolečina v trebuhu, trebušna distenzija, nelagodje v trebuhu, navzea, bruhanje, driska Motnje reprodukcije in dojk Zelo pogosti:
Pergoveris pre-filled pen treatment diary (See table at the end)
Dnevnik zdravljenja z zdravilom Pergoveris napolnjen injekcijski peresnik (glejte preglednico na koncu)
Other ingredients:
Druge sestavine zdravila so:
The prevalence of ectopic pregnancy after assisted reproductive technologies (ART) was reported to be higher than in the general population.
Po postopkih asistirane reprodukcije (ART - Assisted Reproductive Technologies) so poročali o višji prevalenci zunajmaternične nosečnosti v primerjavi s splošno populacijo.
The following symptomatology may be observed in severe cases of OHSS: abdominal pain, abdominal distension, severe ovarian enlargement, weight gain, dyspnoea, oliguria and gastrointestinal symptoms including nausea, vomiting and diarrhoea.
V hudih primerih OHSS lahko opazimo naslednje znake: bolečine v trebuhu, povečanje trebuha, hudo povečanje jajčnikov, pridobivanje telesne mase, dispnejo, oligurijo in gastrointestinalne znake vključno s slabostjo, bruhanjem in drisko.
This will then release an egg, after an injection of the hormone “human chorionic gonadotropin (hCG)”.
Ta nato po injiciranju hormona „humani horionski gonadotropin (hCG)“ sprosti jajčece.
• If needed, turn the dose setting knob backward to correct the dose.
• Po potrebi obračajte gumb za nastavitev odmerka nazaj do pravilnega odmerka.
• Turn the dose setting knob forward to dial up according to the dose that was prescribed by your doctor.
• Gumb za nastavitev odmerka obračajte naprej do odmerka, ki vam ga je predpisal zdravnik.
• Screw the threaded tip of the Pergoveris pre-filled pen into the outer needle cap until you feel a light resistance.
• Privijajte navojno konico zdravila Pergoveris napolnjenega injekcijskega peresnika v zunanji pokrovček injekcijske igle, dokler ne začutite rahlega upora.
Pack sizes of 1, 3 and 10 vials with the corresponding number of solvent's vial (1, 3 and 10 vials).
Zdravilo je na voljo v velikostih pakiranja po 1, 3 in 10 vial z ustreznim številom vial vehikla (1, 3 in
In case of exposure during pregnancy, clinical data are not sufficient to exclude a teratogenic effect of Pergoveris.
Za zdravilo Pergoveris ni na voljo kliničnih podatkov od nosečnic, ki so bile izpostavljene zdravilu, da bi izključili teratogene učinke zdravila Pergoveris.
What Pergoveris looks like and contents of the pack Pergoveris is presented as a clear, colourless to slightly yellow solution for injection in a mulitidose pre-filled pen:
Izgled zdravila Pergoveris in vsebina pakiranja Zdravilo Pergoveris je na voljo v obliki bistre, brezbarvne do rumenkaste raztopine za injiciranje v večodmernem napolnjenem injekcijskem peresniku:
Gently turn the dose setting knob clockwise until it reads 25 in the Dose Feedback Window.
Gumb za nastavitev odmerka nežno obračajte do odčitka 25 v oknu za prikaz odmerka.
• Insert the needle into the vial, push the plunger to expel the air.
• Vstavite injekcijsko iglo v vialo in potisnite bat, da iztisnite zrak.
• Get a new needle - only use the "single-use" needles supplied.
• Vzemite novo injekcijsko iglo - uporabljajte samo igle za
Pergoveris is for an immediate and single use following first opening and reconstitution.
Zdravilo Pergoveris je treba po prvem odprtju in rekonstituciji porabiti takoj.
Complication of severe OHSS General disorders and administration site conditions Very common:
Splošne težave in spremembe na mestu aplikacije Zelo pogosti:
Turn the dose setting knob until your intended dose shows in the Dose Feedback Window.
Gumb za nastavitev odmerka obračajte, dokler v oknu za prikaz odmerka ni prikazan predvideni odmerek.
Very common (may affect more than 1 in 10 people):
Zelo pogosti (pojavijo se lahko pri več kot 1 od 10 bolnic)
Adverse reactions are listed below by MedDRA system organ class and by frequency.
Neželeni učinki so spodaj razvrščeni po organskih sistemih in pogostnosti glede na klasifikacijo MedDRA.
Pergoveris solution for injection in pre-filled pen must not be administered as a mixture with other medicinal products in the same injection.
Zdravilo Pergoveris raztopina za injiciranje v napolnjenem injekcijskem peresniku se ne sme dajati v obliki mešanice z drugimi zdravili v isti injekcijski brizgi.
Pergoveris contains two different active substances called “follitropin alfa” and “lutropin alfa”.
Zdravilo Pergoveris vsebuje dve različni učinkovini, imenovani „folitropin alfa“ in „lutropin alfa“.
A treatment regimen commences with the recommended dose of Pergoveris containing 150 IU r-hFSH/75 IU r-hLH daily.
Režim zdravljenja se začne s priporočenim odmerkom zdravila Pergoveris, ki vsebuje 150 i.e. r-hFSH/75 i.e. r-hLH na dan.
• Hold the Pergoveris pre-filled pen firmly with one hand, and slip the needle into the outer needle cap.
• Držite zdravilo Pergoveris napolnjen injekcijski peresnik čvrsto z eno roko in potisnite iglo v zunanji pokrovček za iglo.
A dose of 25 IU r-hLH daily (in combination with 150 IU r-hFSH) resulted in insufficient follicular development.
Z dnevnim odmerkom 25 i.e. r-hLH (v kombinaciji s 150 i.e. r-hFSH), je bil dosežen razvoj foliklov nezadosten.
• Then withdraw the needle and clean the skin with a new alcohol swab using a circular motion.
• Nato izvlecite iglo in s krožnimi gibi z novo alkoholno blazinico očistite kožo.
Warning: Always make sure to use a new needle for each injection.
Opozorilo: Po vsakem injiciranju uporabite novo injekcijsko iglo.
Get together everything you need and lay them out
Pripravite in razvrstite vse, kar potrebujete:
• Contains 1.44 mL of Pergoveris solution
• Vsebuje 1,44 ml raztopine zdravila Pergoveris.
EXP Once opened, the medicinal product may be stored for a maximum of 28 days at 25°C.
EXP Odprto zdravilo lahko shranjujete največ 28 dni pri 25 °C.
When undergoing stimulation of your ovaries to produce eggs, you are more likely to have a miscarriage than the average woman.
Pri tehnikah asistirane reprodukcije ali stimulacije jajčnikov za tvorbo jajčec je verjetnost splava večja kot pri povprečnih ženskah.
A dose of 75 IU r-hLH daily (in combination with 150 IU r-hFSH) resulted in adequate follicular development and oestrogen production.
Z dnevnim odmerkom 75 i.e. r-hLH (v kombinaciji s 150 i.e. r-hFSH) so dosegli primeren razvoj foliklov in izločanje estrogena.
• The Pergoveris pre-filled pen is for subcutaneous injection only.
• Zdravilo Pergoveris napolnjen injekcijski peresnik je samo za subkutano injiciranje.
Mild to severe injection site reactions (e.g. pain, erythema, haematoma, bruising, swelling and/or irritation at the site of injection)
blage do resne reakcije na mestu injiciranja (npr. bolečina, eritem, hematom, modrice, oteklina in/ali razdraženost na mestu injiciranja)
Pergoveris may be mixed with follitropin alfa and co-administered as a single injection.
Zdravilo Pergoveris lahko mešate s folitropinom alfa in ga dajete sočasno kot eno samo injekcijo.
Verify that the Dose Feedback Window reads "0" (Fig. 8).
Preverite, ali je odčitek v oknu za prikaz odmerka "0" (sl. 8).
Colourless 3 mL glass cartridge (type I borosilicate glass, with a grey bromobutyl rubber plunger stopper and a crimp cap made with grey rubber stopper septum and aluminium) pre-assembled in a pre-filled pen.
Brezbarvni 3-ml stekleni vložek (borosilikatno steklo tipa I s sivim batnim zamaškom iz bromobutilne gume in zgibano zaporko iz sivega gumijastega tesnila in aluminija), sestavljen v napolnjenem injekcijskem peresniku.
• Needles (included in the pack)
• injekcijske igle (vključene v pakiranju),
• Repeat Section 4 (Getting familiar with your Pergoveris pre-filled pen) through Section 5
• Ponovite poglavje 4 (Seznanitev z deli zdravila Pergoveris napolnjen injekcijski peresnik)
This increases your risk of developing ovarian hyperstimulation syndrome (OHSS).
S tem se poveča tveganje za razvoj sindroma hiperstimulacije jajčnikov ali OHSS.
• Confirm you receive a complete injection (column 7) OR record the number shown in the Dose
• Potrdite, da ste prejeli celo injekcijo (stolpec 7) ALI zabeležite številko, prikazano v oknu za prikaz odmerka, v kolikor ni "0" (stolpec 8).
After reconstitution, each mL of the solution contains 150 IU follitropin alfa and 75 IU lutropin alfa per milliliter.
Po rekonstituciji vsak ml raztopine vsebuje 150 i.e. folitropina alfa in 75 i.e. lutropina alfa na mililiter.
When an optimal response is obtained, a single injection of 250 micrograms of r-hCG or 5,000 IU to 10,000 IU hCG should be administered 24-48 hours after the last Pergoveris injection.
Ko je dosežen optimalni odziv, se mora v 24-48 urah po zadnji injekciji zdravila Pergoveris dati eno samo injekcijo z 250 mikrogrami r-hCG ali 5.000 i.e. do 10.000 i.e. hCG. Bolnici svetujemo, da ima spolni odnos na sam dan in dan po tistem, ko je dobila hCG.
Powder and solvent for solution for injection.
prašek in vehikel za raztopino za injiciranje.
• Firmly pinch the skin together and insert the needle at a 45° to 90 angle using a dart-like motion.
• Trdno stisnite kožo in z gibom, podobnim metu sulice, zabodite iglo pod kotom 45º do 90º.
Following intravenous administration, follitropin alfa is distributed to the extracellular fluid space with an initial half-life of around 2 hours and eliminated from the body with a terminal half-life of about one day.
Po intravenskem dajanju, se folitropin alfa porazdeli v zunajcelični prostor z začetnim razpolovnim časom približno 2 uri in izloči iz telesa s končnim razpolovnim časom približno en dan. Volumen porazdelitve v stanju dinamičnega ravnovesja je 10 l.
A treatment regimen commences with the recommended dose of Pergoveris containing 150 International Units (IU) of follitropin alfa and 75 IU of lutropin alfa every day.
Režim zdravljenja se začne s priporočenim odmerkom zdravila Pergoveris, ki vsebuje 150 i.e. folitropina alfa in 75 i.e. lutropina alfa vsak dan.
Fig. 1
Sl. 1
This side effect is common.
Ta neželeni učinek je pogost.
You can use Pergoveris with a licensed follitropin alfa preparation as separate injections, if prescribed by your doctor.
Zdravilo Pergoveris lahko uporabljate s pripravkom folitropina alfa z dovoljenjem za promet v ločenih injekcijah, če tako predpiše zdravnik.
• Contains 0.72 mL of Pergoveris solution
• Vsebuje 0,72 ml raztopine zdravila Pergoveris.
The pH of the solution is 6.5 - 7.5, its osmolality is 250 - 400 mOsm/kg.
FARMACEVTSKA OBLIKA raztopina za injiciranje (injekcija) Bistra, brezbarvna do rumenkasta raztopina pH raztopine je 6,5 - 7,5; osmolalnost je 250 - 400 mOsm/kg.
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity.
Predklinični podatki na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih odmerkih in genotoksičnosti ne kažejo posebnega tveganja za človeka.
Pergoveris solution for injection in pre-filled pen may be administered concomitantly with a licensed follitropin alfa preparation as separate injections.
Zdravilo Pergoveris raztopina za injiciranje v napolnjenem injekcijskem peresniku se lahko daje sočasno s pripravkom folitropina alfa z dovoljenjem za promet v ločenih injekcijah.
Take off the pen cap.
Snemite pokrovček peresnika.
Fig. 9
Sl. 9
Pergoveris is intended for subcutaneous administration.
Zdravilo Pergoveris se daje subkutano.
• abdominal cramp or bloating.
• trebušni krči ali napihnjenost
• Turn the vial upside down, gently draw the solution back into the syringe.
• Obrnite vialo navpično navzdol in previdno potegnite raztopino nazaj v brizgo.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Solvent for Pergoveris
IME ZDRAVILA IN POT(I) UPORABE vehikel za Pergoveris voda za injekcije
After reconstitution, each mL of the solution contains 150 IU r-hFSH and 75 IU r-hLH per milliliter.
Po rekonstituciji vsak ml raztopine vsebuje 150 i.e. r-hFSH in 75 i.e. r-hLH na mililiter.
Your doctor will ensure, careful monitoring of the ovarian response, based on ultrasound and blood tests (oestradiol measurements) before and during the course of treatment.
Pred samim zdravljenjem in tudi med njim bo zdravnik poskrbel za skrbno spremljanje ovarijskega odziva z ultrazvokom in krvnimi testi (meritve estradiola).
Once opened, the product may be stored for a maximum of 28 days at 25°C.
Odprto zdravilo se lahko shranjuje največ 28 dni pri 25 °C.
The effects of an overdose of Pergoveris are unknown, nevertheless one could expect OHSS to occur.
Če ste uporabili večji odmerek zdravila Pergoveris, kot bi smeli Učinki prevelikega odmerka zdravila Pergoveris niso znani, vendar pa lahko pričakujemo pojav OHSS.
Warning: Never reuse any used needle.
Opozorilo: Nikoli ponovno ne uporabite že uporabljene injekcijske igle.
EU/1/07/396/002
EU/1/07/396/001 EU/1/07/396/002 EU/1/07/396/003
Pharmacotherapeutic group: Sex hormones and modulators of the genital system, gonadotropins.
Farmakoterapevtska skupina: spolni hormoni in zdravila za uravnavanje delovanja spolovil, gonadotropni hormoni; oznaka ATC: G03GA30.
Getting familiar with the parts of your Pergoveris pre-filled pen Getting your Pergoveris pre-filled pen ready for injection Setting the dose prescribed by your doctor Injecting the dose
Seznanitev z deli zdravila Pergoveris napolnjen injekcijski peresnik Priprava zdravila Pergoveris napolnjen injekcijski peresnik na injiciranje Nastavitev odmerka, ki ga je predpisal zdravnik Injiciranje odmerka
This is whether the pregnancy is obtained by spontaneous conception or with fertility treatments.
To se lahko zgodi ne glede na to, ali so zanosile spontano ali s pomočjo zdravljenja.
Mild to severe hypersensitivity reactions including anaphylactic reactions and shock Nervous system disorders Very common:
blage do hude reakcije preobčutljivosti, vključno z anafilaktičnimi reakcijami in šokom
Warning: Do not reuse needles.
Opozorilo: injekcijskih igel ne uporabite ponovno.
Do not use this medicine after the expiry date which is stated on the vials and the carton after EXP.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na vialah in škatli poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
Getting the syringe ready for injection
Priprava brizge na injiciranje
3), and volume of your pen (column 4).
(stolpec 3) in količino v peresniku (stolpec 4).
1 multidose pre-filled pen of 1.44 mL solution 14 injection needles
1 večodmerni napolnjen injekcijski peresnik z 1,44 ml raztopine 14 injekcijskih igel
• Turn the vial upside down and gently draw up all the water (solvent).
• Obrnite vialo navpično navzdol in previdno izvlecite vso vodo
Proceed directly to Section 6: Setting the dose prescribed by your doctor.
Takoj nadaljujte na poglavju 6: Nastavitev odmerka, ki ga je predpisal zdravnik.
• Contains 900 IU follitropin alfa and 450 IU lutropin alfa.
• Vsebuje 900 i.e. folitropina alfa in 450 i.e. lutropina alfa.
• The numbers in the Dose Feedback Window present the number of International Units, or IUs,
• Številke v okencu za prikaz odmerka predstavljajo število mednarodnih enot (i.e.)
• 1 fine bore needle for injection under the skin
• 1 fina igla za podkožno injiciranje
Treatment is directed to symptoms.
Simptomatsko zdravljenje.
Once you have finished your injection, immediately discard all needles and empty vials in your sharps container.
Vse uporabljene injekcijske igle in prazne viale zavrzite takoj po injiciranju v posodo za ostre predmete.
• Continue by pushing the capped needle against a firm surface until you hear a “click”.
• Nadaljujte s potiskanjem igle s pokrovčkom proti trdni površini,
• Set the dose to the missing amount you recorded in the treatment diary OR the number still displayed in the Dose Feedback Window on your previous pen, and inject.
• Nastavite odmerek na manjkajočo količino, ki ste jo zabeležili v dnevnik zdravljenja, ALI
• Contains 450 IU follitropin alfa and 225 IU lutropin alfa.
• Vsebuje 450 i.e. folitropina alfa in 225 i.e. lutropina alfa.
Ovarian torsion
Torzija jajčnika
How to use Pergoveris
Kako uporabljati zdravilo Pergoveris
Proceed to Section 6: Setting the dose prescribed by your doctor.
Nadaljujte na poglavju 6: Nastavitev odmerka, ki ga je predpisal zdravnik.
1 multidose pre-filled pen of 0.72 mL solution 7 injection needles
1 večodmerni napolnjen injekcijski peresnik z 0,72 ml raztopine 7 injekcijskih igel